Table 3.
Comparison of pre-treatment PLR < 83 and PLR > 83 groups
| Pre-treatment PLR < 83 (n = 17) | Pre-treatment PLR ≥ 83 (n = 25) | P-value | |
|---|---|---|---|
| Mean age in years (s.d.) | 59.0 (9.1) | 72.1 (9.6) | 0.001 |
| Males | 14 (82.4%) | 16 (64.0%) | 0.300 |
| Hepatitis B | 2 (11.8%) | 3 (12.0%) | 1.000 |
| Hepatitis C | 11 (64.7%) | 8 (32.0%) | 0.059 |
| Alcohol abuse | 5 (29.4%) | 9 (36.0%) | 0.747 |
| NASH/NAFLD | 3 (17.6%) | 10 (40.0%) | 0.179 |
| Mean BMI (s.d.) | 26.9 (4.4) | 26.5 (5.3) | 0.772 |
| Smoking history | 12 (70.6%) | 15 (60.0%) | 0.531 |
| Diabetes mellitus | 5 (29.4%) | 12 (48.0%) | 0.339 |
| Hyperlipidemia | 3 (17.6%) | 16 (64.0%) | 0.004 |
| Hypertension | 12 (70.6%) | 20 (80.0%) | 0.714 |
| ALBI grade ≥ 2 | 7 (41.2%) | 16 (64.0%) | 0.209 |
| Child-Pugh class B | 0 (0.0%) | 9 (36.0%) | 0.006 |
| Mean platelets (109/L) (s.d.) | 97.5 (51.1) | 186.2 (75.2) | 0.001 |
| Mean lymphocytes (109/L) (s.d.) | 1.67 (0.68) | 1.24 (0.62) | 0.048 |
| Mean AFP in ng/mL (s.d.) | 516 (1163) | 3048 (9757) | 0.211 |
| Normal AFP | 10 (58.8%) | 14 (56.0%) | 1.000 |
| Mean total tumor size in cm (s.d.) | 6.3 (4.0) | 7.5 (4.0) | 0.359 |
| Number of tumors (s.d.) | 2.06 (1.09) | 1.48 (1.00) | 0.090 |
OPLR: platelet-to-lymphocyte ratio; s.d.: standard deviation; NASH: non-alcoholic steatohepatitis; NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; ALBI: albumin-bilirubin; AFP: alpha-fetoprotein